PSMD5

26S proteasome non-ATPase regulatory subunit 5 · Q16401 · PSMD5 on Sugi Atlas →

0 patent compounds predicted against PSMD5, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PSMD5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis PHASE1WITHDRAWN
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma PHASE1COMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Effect of Diaphragm Stimulation During Surgery nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Implementation of Molecular Diagnostic Pathways nanUNKNOWN
Quantification of GADD34 Expression in RA nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PSMD5 binder may also engage these)

ProteinNameSimilarity
Q0P5A6 1.000 Q0P5A6 →
Q5IFJ8 1.000 Q5IFJ8 →
Q8BJY1 1.000 Q8BJY1 →
Q84ZC0 0.989 Q84ZC0 →
Q9LX65 0.987 Q9LX65 →
Q0V9L1 0.985 Q0V9L1 →
Q68F38 0.985 Q68F38 →
Q91YE6 0.985 Q91YE6 →
Q924C1 0.985 Q924C1 →
IPO9 Importin-9 0.985 landscape →
Q9I8E6 0.984 Q9I8E6 →
Q4R4Y2 0.984 Q4R4Y2 →
Q6DCF2 0.984 Q6DCF2 →
ATP6V1H V-type proton ATPase subunit H 0.983 landscape →
Q66L58 0.983 Q66L58 →
Q2TBW0 0.983 Q2TBW0 →
Q9YHB5 0.983 Q9YHB5 →
XPO5 Exportin-5 0.983 landscape →
Q16537 0.983 Q16537 →
B0F9L4 0.983 B0F9L4 →
Q9QXK3 0.982 Q9QXK3 →
A2VE70 0.982 A2VE70 →
Q5T2E6 0.982 Q5T2E6 →
Q9H892 0.982 Q9H892 →
F1QWA8 0.982 F1QWA8 →
Q9QZE5 0.982 Q9QZE5 →
O46563 0.982 O46563 →
Q8JGR7 0.982 Q8JGR7 →
P53620 0.982 P53620 →
COPG1 Coatomer subunit gamma-1 0.982 landscape →